Showing results (71-80 of 126) with videos related to

Sort By:
Pageof 13
Current Urology|July 19, 2019
Laparoscopic Training in Urology Residency Programs: A Systematic ReviewTiago Ribeiro de Oliveira, Ben Van Cleynenbreugel, Sérgio Pereira, et al.
European Urology|August 27, 2013
Early salvage radiotherapy following radical prostatectomyDavid Pfister, Michel Bolla, Alberto Briganti, et al.
European Urology|September 18, 2017
Key Steps in Conducting Systematic Reviews for Underpinning Clinical Practice Guidelines: Methodology of the European Association of UrologyThomas Knoll, Muhammad Imran Omar, Steven Maclennan, et al.
European Urology|July 17, 2012
Mapping of pelvic lymph node metastases in prostate cancerSteven Joniau, Laura Van den Bergh, Evelyne Lerut, et al.
Critical Reviews in Oncology/Hematology|December 10, 2016
Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trialsJulia Menichetti, Silvia Villa, Tiziana Magnani, et al.
Scientific Reports|September 27, 2018
Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scoresThomas Gevaert, Yves-Rémi Van Eycke, Thomas Vanden Broeck, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2005
Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911)Laurence Collette, Hein van Poppel, Michel Bolla, et al.
Clinical Chemistry|June 18, 2005
Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practiceGyörgy Sölétormos, Axel Semjonow, Paul E C Sibley, et al.
Plos One|December 28, 2020
The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patientsThomas Gevaert, Yves-Rémi Van Eycke, Thomas Vanden Broeck, et al.
The Journal of Urology|May 15, 2012
Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive diseaseMartin Spahn, Alberto Briganti, Umberto Capitanio, et al.
Pageof 13